This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignee: Reprise Pharmaceuticals, Inc.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Marc Freichel: Innovator in Neurodegenerative Disease Treatment
Introduction
Marc Freichel is a notable inventor based in Saarlouis, Germany. He has made significant contributions to the field of neurodegenerative disease treatment through his innovative research and development efforts. His work focuses on compounds that inhibit the TRPM4 ion channel, which plays a crucial role in various neurodegenerative conditions.
Latest Patents
Marc Freichel holds 1 patent for his invention titled "Method of treating or preventing neurodegeneration." This patent describes a compound effective in inhibiting the function of the TRPM4 ion channel. The invention aims to treat or prevent neurodegenerative diseases such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis. Additionally, it includes a pharmaceutical composition comprising a TRPM4 inhibitory compound and methods for identifying pharmaceutically active compounds for treating these diseases.
Career Highlights
Marc Freichel is currently associated with Reprise Pharmaceuticals, Inc., where he continues to advance his research in neurodegenerative diseases. His work is pivotal in developing new therapeutic strategies that could significantly impact patient care and treatment outcomes.
Collaborations
He collaborates with talented individuals in his field, including Manuel Friese and Benjamin Schattling. Their combined expertise enhances the research efforts at Reprise Pharmaceuticals, Inc.
Conclusion
Marc Freichel's innovative work in the treatment of neurodegenerative diseases showcases his commitment to advancing medical science. His contributions have the potential to improve the lives of many individuals affected by these challenging conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile